Literature DB >> 34209146

Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Razieh Hassannejad1, Hamsa Sharrouf2, Fahimeh Haghighatdoost1, Ben Kirk2,3,4, Farzad Amirabdollahian2.   

Abstract

BACKGROUND: Metabolic Syndrome (MetS) is a cluster of risk factors for diabetes and cardiovascular diseases with pathophysiology strongly linked to aging. A range of circulatory metabolic biomarkers such as inflammatory adipokines have been associated with MetS; however, the diagnostic power of these markers as MetS risk correlates in elderly has yet to be elucidated. This cross-sectional study investigated the diagnostic power of circulatory metabolic biomarkers as MetS risk correlates in older adults.
METHODS: Hundred community dwelling older adults (mean age: 68.7 years) were recruited in a study, where their blood pressure, body composition and Pulse Wave Velocity (PWV) were measured; and their fasting capillary and venous blood were collected. The components of the MetS; and the serum concentrations of Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Plasminogen Activator Inhibitor-I (PAI-I), Leptin, Adiponectin, Resistin, Cystatin-C, C-Reactive Protein (CRP), insulin and ferritin were measured within the laboratory, and the HOMA1-IR and Atherogenic Index of Plasma (AIP) were calculated.
RESULTS: Apart from other markers which were related with some cardiometabolic (CM) risk, after Bonferroni correction insulin had significant association with all components of Mets and AIP. These associations also remained significant in multivariate regression. The multivariate odds ratio (OR with 95% confidence interval (CI)) showed a statistically significant association between IL-6 (OR: 1.32 (1.06-1.64)), TNF-α (OR: 1.37 (1.02-1.84)), Resistin (OR: 1.27 (1.04-1.54)) and CRP (OR: 1.29 (1.09-1.54)) with MetS risk; however, these associations were not found when the model was adjusted for age, dietary intake and adiposity. In unadjusted models, insulin was consistently statistically associated with at least two CM risk factors (OR: 1.33 (1.16-1.53)) and MetS risk (OR: 1.24 (1.12-1.37)) and in adjusted models it was found to be associated with at least two CM risk factors and MetS risk (OR: 1.87 (1.24-2.83) and OR: 1.25 (1.09-1.43)) respectively. Area under curve (AUC) for receiver operating characteristics (ROC) demonstrated a good discriminatory diagnostics power of insulin with AUC: 0.775 (0.683-0.866) and 0.785 by cross validation and bootstrapping samples for at least two CM risk factors and AUC: 0.773 (0.653-0.893) and 0.783 by cross validation and bootstrapping samples for MetS risk. This was superior to all other AUC reported from the ROC analysis of other biomarkers. Area under precision-recall curve for insulin was also superior to all other markers (0.839 and 0.586 for at least two CM risk factors and MetS, respectively).
CONCLUSION: Fasting serum insulin concentration was statistically linked with MetS and its risk, and this link is stronger than all other biomarkers. Our ROC analysis confirmed the discriminatory diagnostic power of insulin as CM and MetS risk correlate in older adults.

Entities:  

Keywords:  association; biomarkers; insulin; metabolic syndrome; older adults

Year:  2021        PMID: 34209146     DOI: 10.3390/nu13072275

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  117 in total

1.  Serum adiponectin and resistin: Correlation with metabolic syndrome and its associated criteria among temiar subtribe in Malaysia.

Authors:  Mohd Nizam Zahary; Nur Sakinah Harun; Rosliza Yahaya; Nik Ahmad Shaiffudin Nik Him; Mohd Adzim Khalili Rohin; Nur Haslinda Ridzwan; Mimie Noratiqah Jumli; Azizul Fadzli Wan Jusoh
Journal:  Diabetes Metab Syndr       Date:  2019-04-25

2.  Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis.

Authors:  Milton Fabian Suárez-Ortegón; Eduardo Ensaldo-Carrasco; Ting Shi; Stela McLachlan; José Manuel Fernández-Real; Sarah H Wild
Journal:  Atherosclerosis       Date:  2018-05-23       Impact factor: 5.162

3.  Plasma cystatin-C and development of coronary heart disease: The PRIME Study.

Authors:  Gérald Luc; Jean-Marie Bard; Céline Lesueur; Dominique Arveiler; Alun Evans; Philippe Amouyel; Jean Ferrieres; Irène Juhan-Vague; Jean-Charles Fruchart; Pierre Ducimetiere
Journal:  Atherosclerosis       Date:  2005-07-25       Impact factor: 5.162

4.  Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey.

Authors:  Mohsen Mazidi; Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Atherosclerosis       Date:  2018-09-15       Impact factor: 5.162

5.  Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.

Authors:  Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

6.  Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations.

Authors:  Ji Eun Yun; Heejin Kimm; Jaeseong Jo; Sun Ha Jee
Journal:  Metabolism       Date:  2009-10-20       Impact factor: 8.694

7.  The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults.

Authors:  Feng-Hsiang Chiu; Chung Hsun Chuang; Wen-Cheng Li; Yi-Ming Weng; Wen-Chih Fann; Hsiang-Yun Lo; Cheng Sun; Shih-Hao Wang
Journal:  Cardiovasc Diabetol       Date:  2012-04-25       Impact factor: 9.951

Review 8.  Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.

Authors:  Krithika Srikanthan; Andrew Feyh; Haresh Visweshwar; Joseph I Shapiro; Komal Sodhi
Journal:  Int J Med Sci       Date:  2016-01-01       Impact factor: 3.738

9.  Association of cystatin C levels with metabolic syndrome incidence: a nested case-control study with propensity score matching.

Authors:  Tengfei Yang; Dongmei Pei
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

Review 10.  Adipokines, metabolic syndrome and rheumatic diseases.

Authors:  Vanessa Abella; Morena Scotece; Javier Conde; Verónica López; Verónica Lazzaro; Jesús Pino; Juan J Gómez-Reino; Oreste Gualillo
Journal:  J Immunol Res       Date:  2014-02-26       Impact factor: 4.818

View more
  2 in total

1.  Association between Metabolic Syndrome and professional category: a cross-sectional study with Nursing professionals.

Authors:  Amália Ivine Costa Santana; Magno Conceição das Merces; Argemiro D'Oliveira Júnior
Journal:  Rev Lat Am Enfermagem       Date:  2022-07-08

Review 2.  Inflammation: A New Look at an Old Problem.

Authors:  Evgenii Gusev; Yulia Zhuravleva
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.